Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
6.44
+0.28 (4.55%)
At close: Aug 4, 2026, 4:00 PM EDT
6.42
-0.02 (-0.31%)
After-hours: Aug 4, 2026, 7:45 PM EDT
Nuvation Bio Employees
Nuvation Bio had 307 employees as of March 31, 2026. The number of employees increased by 34 or 12.45% compared to the same quarter last year.
Employees
307
Change
34
Growth
12.45%
Revenue / Employee
$465,948
Profits / Employee
-$475,550
Market Cap
2.24B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 307 | 34 | 12.45% |
| Dec 31, 2025 | 298 | 78 | 35.45% |
| Sep 30, 2025 | 291 | 88 | 43.35% |
| Jun 30, 2025 | 278 | 111 | 66.47% |
| Mar 31, 2025 | 273 | 114 | 71.70% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Sep 30, 2024 | 203 | 150 | 283.02% |
| Jun 30, 2024 | 167 | 113 | 209.26% |
| Mar 31, 2024 | 159 | 106 | 200.00% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Sep 30, 2023 | 53 | -1 | -1.85% |
| Jun 30, 2023 | 54 | -31 | -36.47% |
| Mar 31, 2023 | 53 | -15 | -22.06% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Sep 30, 2022 | 54 | -4 | -6.90% |
| Jun 30, 2022 | 85 | 34 | 66.67% |
| Mar 31, 2022 | 68 | 30 | 78.95% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Vericel | 398 |
| Vera Therapeutics | 339 |
| Harmony Biosciences Holdings | 293 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
| Pharvaris | 134 |
| Mineralys Therapeutics | 76 |
NUVB News
- 14 hours ago - Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses - PRNewsWire
- 8 days ago - Nuvation Bio price target raised to $21 from $17 at H.C. Wainwright - TheFly
- 13 days ago - Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - PRNewsWire
- 15 days ago - RBC looks for Nuvation shares to appreciate as safusidenib data builds - TheFly
- 15 days ago - Nuvation Bio Slides: Corporate presentation - Filings
- 15 days ago - Nuvation Bio announces data from the Phase 2 J201 study - TheFly
- 15 days ago - Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma - PRNewsWire
- 26 days ago - 3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts - TipRanks